Targeting distinct pathogenetic pathways that drive disease progression has reached the stage of active drug development programs for disease modification with drugs targeting -synuclein, GBA-1, LRRK-2 and GLP1 receptors comprising the largest group of recent and ongoing disease modification trials in PD
In the future, precision medicine, guided by genetic variants, represents a promising avenue for tailoring hyperuricemia management to individualized needs
Subsequently, the following eligibility criteria were applied: a) healthy human subjects
determining if differences in selection of anticoagulant type negatively impacts translation of REDOX related findings to clinical populations
Nephrol Dial Transplant (2015) 30(Suppl 4):iv607
The Glutathione 10%/Ascorbic Acid 5% Topical Cream is a semisolid preparation dispensed in a pump mechanism, designed for convenient and controlled application on the skin